Cullinan Oncology, Inc.
https://www.cullinanoncology.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cullinan Oncology, Inc.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.
Strong Sales, Deals Propel China Biotechs To 2023 Profitability
Strong sales growth and licensing activity in 2023 helped multiple Chinese biotechs to a solid profit performance, some moving into the black for the first time.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 1: Business Strategy And Leadership
Global crises and a tough funding environment mean biopharma leadership teams need to work hard to survive, let alone thrive. Industry executives shared their predictions and advice on strategy for 2024.
Scrip Asks...What Does 2023 Hold For Biopharma? Part 1: The Funding Environment
With valuations down and borrowing costs up, many industry insiders are expecting Darwinian scenes in biotech this year. Survival of the fittest is the order of the day: companies with riskier, less commercially defined propositions will struggle, while platform companies with multiple shots on strong goals will increasingly find favor in a more risk-averse environment.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Cullinan Florentine
- Cullinan Management, Inc.
- Cullinan MICA
- Cullinan Pearl
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice